Novavax Inc (NVAX) stock
NVAXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$8.53−0.23 (-2.68%)
Close on Nov 13, 2026Market cap $1.41BP/E –Yield –
Novavax enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Novavax's enterprise value was $925.52M on Nov 11, 2026, against $367.19M a year earlier. Over the last 5 years it ranged from -$752.59M to $8.84B, with a median of $467.20M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $925.52M | +195.2% |
| 2025 | Dec 31, 2025 | $313.57M | -13.6% |
| 2024 | Dec 31, 2024 | $363.10M | – |
| 2023 | Dec 29, 2023 | -$96.46M | – |
| 2022 | Dec 30, 2022 | -$486.28M | -105.5% |
| 2021 | Dec 31, 2021 | $8.84B | +37.2% |
| 2020 | Dec 31, 2020 | $6.45B | +25005.0% |
| 2019 | Dec 31, 2019 | $25.67M | -95.4% |
| 2018 | Dec 31, 2018 | $558.58M | +163.4% |
| 2017 | Dec 29, 2017 | $212.02M | +411.2% |
| 2016 | Dec 30, 2016 | $41.48M | -97.9% |
| 2015 | Dec 31, 2015 | $1.97B | +43.0% |
| 2014 | Dec 31, 2014 | $1.38B | +45.8% |
| 2013 | Dec 31, 2013 | $946.73M | +303.1% |
| 2012 | Dec 31, 2012 | $234.83M | +79.5% |
| 2011 | Dec 30, 2011 | $130.80M | – |
See a number that looks wrong?